ACA
XERS icon

American Capital Advisory’s Xeris Biopharma Holdings XERS Stock Holding History

American Capital Advisory’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$143 – 506
2024
Q3 		$143 Buy
+50
New +$128 ﹤0.01% 452

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Capital Advisory's XERS Position: Q4 2024 in Review

American Capital Advisory sold out of Xeris Biopharma Holdings (XERS) in Q4 2024, closing a stake of 50 shares — an estimated $143 sold.

American Capital Advisory first reported a position in XERS in Q3 2024 and held it in 1 quarter. The position peaked at $143 in Q3 2024. 162 funds tracked by Wall St. Rank hold XERS as of Q4 2024.

  • American Capital Advisory reported no remaining Xeris Biopharma Holdings position as of Q4 2024 after selling out during the quarter.
  • American Capital Advisory sold 50 Xeris Biopharma Holdings shares in Q4 2024, an estimated $143.
  • American Capital Advisory first reported a position in Xeris Biopharma Holdings in Q3 2024 and held it in 1 quarter.
  • American Capital Advisory's Xeris Biopharma Holdings position peaked at $143 in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2024.

Based on American Capital Advisory's 13F filing for Q4 2024, filed 28 Jan 2025.